Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “therapy”

782 pharma patents match "therapy" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 782
Index total 30,257
Page 5 / 33

Quick answer

This filtered view shows 782 pharmaceutical patents matching "therapy" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

782 results for “therapy” · 30,257 patents in full index Clear search

  1. US 11971410

    Methods of classifying response to immunotherapy for cancer

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Apr 30, 2024 · Expires Apr 25, 2044

    granted
  2. US 11965161

    Methods and compositions for sensitization of tumor cells to immune therapy

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 23, 2024 · Expires Apr 18, 2044

    granted
  3. US 11938124

    Combination therapy for treatment of cancer

    PMV PHARMACEUTICALS, INC. · Granted Mar 26, 2024 · Expires Mar 21, 2044

    granted
  4. US 11939596

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Mar 26, 2024 · Expires Mar 21, 2044

    granted
  5. US 11926824

    miRNA biogenesis in exosomes for diagnosis and therapy

    The Board of Regents of the University of Texas System · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  6. US 11925642

    Regulation of eIF4E activity for migraine therapy

    The Board of Regents of the University of Texas System · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  7. US 11925663

    Methods of managing tumor flare in adoptive immunotherapy

    Atara Biotherapeutics, Inc. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  8. US 11925664

    Intracellular genomic transplant and methods of therapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  9. US 11918660

    Viral vectors for cancer therapy

    Krystal Biotech, Inc. · Granted Mar 5, 2024 · Expires Feb 29, 2044

    granted
  10. US 11919937

    T cell receptors for immunotherapy

    The Board of Regents of the University of Texas System · Granted Mar 5, 2024 · Expires Feb 29, 2044

    granted
  11. US 11920132

    Oligonucleotide therapy for Leber congenital amaurosis

    ProQR Therapeutics II B.V. · Granted Mar 5, 2024 · Expires Feb 29, 2044

    granted
  12. US 11903966

    Intracellular genomic transplant and methods of therapy

    Regents of the University of Minnesota · Granted Feb 20, 2024 · Expires Feb 15, 2044

    granted
  13. US 11898180

    Compositions and methods for amino acid depletion therapy

    Avalon Polytom (HK) Limited · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  14. US 11878049

    Mitapivat therapy and modulators of cytochrome P450

    Agios Pharmaceuticals, Inc. · Granted Jan 23, 2024 · Expires Jan 18, 2044

    granted
  15. US 11865122

    Estrogen therapy for brain gray matter atrophy and associated disability

    The Regents of the University of California · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted
  16. US 11866515

    Hemiasterlin derivatives for conjugation and therapy

    Sutro Biopharma, Inc. · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted
  17. US 11866742

    Fusion proteins comprising enzyme replacement therapy enzymes

    DENALI THERAPEUTICS INC. · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted
  18. US 11866688

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted
  19. US 11865186

    Gene therapy treatment of atrial fibrillation

    Northwestern University · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted
  20. US 11857528

    Methods of providing solriamfetol therapy to subjects with impaired renal function

    AXSOME MALTA LTD. · Granted Jan 2, 2024 · Expires Dec 28, 2043

    granted
  21. US 11850226

    Methods of providing solriamfetol therapy to subjects with impaired renal function

    AXSOME MALTA LTD. · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  22. US 11850227

    Methods of providing solriamfetol therapy to subjects with impaired renal function

    AXSOME MALTA LTD. · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  23. US 11850228

    Methods of providing solriamfetol therapy to subjects with impaired renal function

    AXSOME MALTA LTD. · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  24. US 11839598

    Methods of providing solriamfetol therapy to subjects with impaired renal function

    AXSOME MALTA LTD. · Granted Dec 12, 2023 · Expires Dec 7, 2043

    granted